XML 63 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements, License Agreement and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Japan [Member]    
Disaggregation of Revenue [Line Items]    
Transaction price, variable consideration from estimated future co-development billing $ 0  
Europe [Member]    
Disaggregation of Revenue [Line Items]    
Transaction price, variable consideration from estimated future co-development billing 0  
U.S./RoW and China [Member]    
Disaggregation of Revenue [Line Items]    
Changes in revenue from changes to estimated variable consideration 0  
Astellas Agreement [Member] | Japan [Member]    
Disaggregation of Revenue [Line Items]    
Changes in revenue from changes to estimated variable consideration 0  
Transaction price, variable consideration from estimated future co-development billing 0 $ 0
Astellas Agreement [Member] | Japan [Member] | Co Development Information Sharing And Committee Services [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 17,100,000  
Astellas Agreement [Member] | Japan [Member] | License [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 100,300,000  
Astellas Agreement [Member] | Europe [Member]    
Disaggregation of Revenue [Line Items]    
Changes in revenue from changes to estimated variable consideration 0  
Astellas Agreement [Member] | Europe [Member] | Co Development Information Sharing And Committee Services [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 288,100,000  
Astellas Agreement [Member] | Europe [Member] | License [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 619,000,000  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co Development Information Sharing And Committee Services [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 625,500,000  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Product [Member]    
Disaggregation of Revenue [Line Items]    
Cumulative Revenue 354,800,000  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 344,500,000  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China Performance Obligation [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration $ 486,900,000